OXiGENE Announces Presentation of Phase 2 Data Confirming That Addition of Fosbretabulin to Bevacizumab Significantly Increases Progression-Free Survival in Recurrent Ovarian Cancer
November 10, 2014 03:00 ET
|
Mateon Therapeutics
- Subgroup Analysis of GOG 186I Study Shows Benefit in Difficult-to-Treat Platinum-Resistant Patients -
- Detailed Results Presented at the International Gynecologic Cancer Society Meeting -...
OXiGENE Announces Third Quarter 2014 Earnings Conference Call and Webcast
October 22, 2014 09:15 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will hold a...
OXiGENE Announces First Patient Enrolled in Phase 1b/2 Study of Fosbretabulin Combined With Pazopanib in Patients With Advanced Recurrent Ovarian Cancer
October 07, 2014 16:01 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 7, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the first patient has...
OXiGENE Announces Presentation of Data From the Phase 2 GOG186I Study at the 15th Biennial Meeting of the International Gynecologic Cancer Society
October 06, 2014 16:01 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 6, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the data from the...
OXiGENE Initiates Phase 2 Study of Fosbretabulin in Gastrointestinal Neuroendocrine Tumors
September 17, 2014 16:01 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the first patient...
OXiGENE Announces Presentation at the Rodman and Renshaw Conference on September 9
August 26, 2014 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
OXiGENE Reports Second Quarter 2014 Financial Results
August 05, 2014 16:00 ET
|
Mateon Therapeutics
- Phase 2 Trial of Fosbretabulin in Gastrointestinal Neuroendocrine Tumors Planned -
- Further Data from Gynecologic Oncology Group (GOG) Phase 2 Ovarian Cancer Trial to be Presented in November...
OXiGENE Announces Second Quarter 2014 Earnings Conference Call and Webcast
July 23, 2014 16:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., July 23, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report second...
OXiGENE, Inc. Announces $16 Million At-The-Market Registered Direct Offering
May 23, 2014 09:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 23, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that it has entered into...
OXiGENE Names Experienced Biotech Executive, David J. Chaplin, Ph.D., as President and Chief Executive Officer
May 16, 2014 08:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 16, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...